Aarti Drugs Valuation
Is 524348 undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score
3/6Valuation Score 3/6
Below Fair Value
Significantly Below Fair Value
Price-To-Earnings vs Peers
Price-To-Earnings vs Industry
Price-To-Earnings vs Fair Ratio
Analyst Forecast
Share Price vs Fair Value
What is the Fair Price of 524348 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: 524348 (₹455.75) is trading above our estimate of fair value (₹215.88)
Significantly Below Fair Value: 524348 is trading above our estimate of fair value.
Key Valuation Metric
Which metric is best to use when looking at relative valuation for 524348?
Key metric: As 524348 is profitable we use its Price-To-Earnings Ratio for relative valuation analysis.
| What is 524348's PE Ratio? | |
|---|---|
| PE Ratio | 27.5x |
| Earnings | ₹1.52b |
| Market Cap | ₹42.26b |
| Key Statistics | |
|---|---|
| Enterprise Value/Revenue | 2x |
| Enterprise Value/EBITDA | 16.7x |
| PEG Ratio | 0.9x |
Price to Earnings Ratio vs Peers
How does 524348's PE Ratio compare to its peers?
| Company | Forward PE | Estimated Growth | Market Cap |
|---|---|---|---|
| Peer Average | 50.2x | ||
509079 Gufic Biosciences | 48.2x | n/a | ₹42.2b |
JSLL Jeena Sikho Lifecare | 57x | n/a | ₹47.7b |
500288 Morepen Laboratories | 30.6x | n/a | ₹41.6b |
524735 Hikal | 64.9x | 49.2% | ₹48.4b |
524348 Aarti Drugs | 27.5x | 31.5% | ₹42.3b |
Price-To-Earnings vs Peers: 524348 is good value based on its Price-To-Earnings Ratio (27.5x) compared to the peer average (50.2x).
Price to Earnings Ratio vs Industry
How does 524348's PE Ratio compare vs other companies in the IN Pharmaceuticals Industry?
| 2 Companies | Price / Earnings | Estimated Growth | Market Cap |
|---|---|---|---|
INDSWFTLAB Ind-Swift Laboratories | 1.6x | n/a | US$72.78m |
524652 Ind-Swift | 2x | n/a | US$13.52m |
| 2 Companies | Estimated Growth | Market Cap |
|---|
Price-To-Earnings vs Industry: 524348 is good value based on its Price-To-Earnings Ratio (27.5x) compared to the Indian Pharmaceuticals industry average (32.2x).
Price to Earnings Ratio vs Fair Ratio
What is 524348's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
| Fair Ratio | |
|---|---|
| Current PE Ratio | 27.5x |
| Fair PE Ratio | 40.7x |
Price-To-Earnings vs Fair Ratio: 524348 is good value based on its Price-To-Earnings Ratio (27.5x) compared to the estimated Fair Price-To-Earnings Ratio (40.7x).
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
Analyst Forecast: Insufficient data to show price forecast.
Discover undervalued companies
Bal Pharma
₹2.1b
Manufactures and markets pharmaceutical formulations and active pharmaceutical ingredients (APIs) in India and internationally.
BALPHARMA
₹134.50
7D
11.6%
1Y
27.4%
Mercury Laboratories
₹1.1b
Develops, manufactures, markets, distributes, and sells pharmaceutical drugs, medicines, and formulations for mother and child healthcare in India and internationally.
538964
₹911.45
7D
-3.5%
1Y
18.7%
Venus Remedies
₹3.9b
Engages in the pharmaceutical business in India and internationally.
VENUSREM
₹298.65
7D
-1.3%
1Y
-16.9%